AeroRx Therapeutics today announced the closing of a $21 million Series A financing led by Avalon BioVentures, with participation from Correlation Ventures, Alexandria Venture Investments, and others. Proceeds will support advancement of AERO-007, the first nebulized LABA/LAMA combination in development for chronic obstructive pulmonary disease (COPD), into late-stage clinical development. Positive Phase 2a study data showed that AERO-007 was well tolerated in patients with moderate to severe COPD, producing rapid-onset, clinically meaningful bronchodilation sustained through 24 hours at both low and high doses. With this financing, AeroRx is preparing to initiate a Phase 2b dose-optimization study and advance toward NDA-enabling development. Read the press release for more: https://lnkd.in/gyicyAqv #COPD #RespiratoryDisease #Biotech #Financing #DrugDelivery #ClinicalTrials
AeroRx Therapeutics
Biotechnology Research
San Diego, California 153 followers
The First Nebulized LABA/LAMA Combination Drug in Development for COPD
About us
AeroRx Therapeutics is a clinical-stage biopharmaceutical company developing proprietary, combination products for nebulized delivery to improve the treatment of chronic respiratory diseases. The company’s lead product candidate, inhaled AERO-007, is the first nebulized LABA/LAMA fixed-dose combination drug in clinical development as a first-line maintenance therapy for chronic obstructive pulmonary disease (COPD) and has the potential to help millions of patients who remain symptomatic, or poorly served, under existing drugs delivered via handheld inhalers or nebulized LABA or LAMA monotherapy. A second program, AERO-111, is in development as the first nebulized LABA/LAMA/ICS triple therapy, for patients who escalate beyond dual bronchodilators. AeroRx’s leadership team has decades of expertise in aerosol drug delivery, clinical development, and regulatory strategy and guided multiple respiratory therapies from concept to regulatory approval. AeroRx is headquartered in the Avalon BioVentures Accelerator in La Jolla, California.
- Website
-
https://aerorxtx.com/
External link for AeroRx Therapeutics
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- San Diego, California
- Type
- Privately Held
- Founded
- 2023
Locations
-
Primary
Get directions
11099 North Torrey Pines Rd
Suite 290
San Diego, California 92037, US
Updates
-
AeroRx Therapeutics today reported positive Phase 2a results for inhaled AERO-007, the first nebulized LABA/LAMA combination in clinical development for chronic obstructive pulmonary disease (COPD). In the randomized, double-blind, placebo-controlled crossover study, single doses of AERO-007 produced rapid-onset and sustained 24-hour bronchodilation at both dose levels and were well tolerated in COPD patients. AERO-007 combines the FDA-approved bronchodilators indacaterol and glycopyrrolate in a proprietary solution formulation for delivery as a fixed-dose combination via a standard jet nebulizer – addressing the large population of COPD patients who remain symptomatic despite guideline-recommended dual LABA/LAMA combination treatment delivered by handheld inhalers. The full Phase 2a dataset will be presented at an upcoming scientific meeting. AeroRx plans to advance AERO-007 into a late-stage, NDA-enabling clinical program. Read the press release for more: https://lnkd.in/ggG4D2ZB #COPD #RespiratoryDisease #Biotech #DrugDelivery #ClinicalTrials
-